1. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

3. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

4. CDK 4 and 6 Inhibitors: Differences in Target and Dosing Regime

5. MONARCH-1: Abemaciclib Monotherapy Activity

6. Side Effects That Require Appropriate Monitoring

7. CDK 4 and 6 Inhibitors in Patients With Brain Metastases

8. Concluding Remarks

9. Concluding Remarks (cont)

10. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer

11. Current CDK 4 and 6 Inhibitors for HR-Positive, HER2-Negative Metastatic Breast Cancer

12. When Do We Use a CDK 4 and 6 Inhibitor?

13. Subgroup Analyses Across Trials Demonstrates Benefit with CDK 4 and 6 Inhibitors

14. FALCON Trial: Fulvestrant vs Anastrozole

15. MONALEESA-2: First-Line Letrozole Plus Ribociclib vs Letrozole Alone

16. Patients With Poor Prognostic Factors May Benefit From Abemaciclib

17. MONALEESA 7: Pre- and Peri-Menopausal Patients

18. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

19. CDK 4 and 6 Inhibitors for the Treatment of HR-Positive, HER2-Negative Breast Cancer

20. MONARCH-2: Results

21. MONARCH-3: Results

22. MONALEESA 7: Pre- and Peri-Menopausal Patients

23. CDK 4 and 6 Inhibitors: Consistent Results

24. Patients With Poor Prognostic Factors May Benefit From Abemaciclib

25. Concluding Remarks

26. CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update

27. CDK 4 and 6 Inhibitors for the Treatment of HR-Positive, HER2-Negative Breast Cancer

28. CDK 4 and 6 Inhibitors: Incidence of Neutropenia

29. Non-Hematological Side Effects Associated With CDK 4 and 6 Therapy

30. Other Side Effects Associated With CDK 4 and 6 Therapy

31. Management of Neutropenia

32. Dose Adjustments for Patients With Non-Hematological Toxicities

33. Concluding Remarks

34. Abbreviations

35. Abbreviations (cont)